Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib
Breast Cancer: Basic and Clinical Research · 2020-01 · 14
DOI: 10.1177/1178223420944864 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Cancer: Basic and Clinical Research, online erschienen am 23.07.2020. Verfasst von Ajay Dhakal und 12 weiteren Autor:innen. Beteiligte Einrichtung: Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, national cancer institute, Clinical Data Network Shared Resources.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Despite the approval of mTOR inhibitor everolimus and CDK4/6 inhibitors in the management of hormone-receptor-positive HER2 non-amplified metastatic breast cancer (HR+ HER2-MBC), the optimal sequence of therapy is unclear. There are no clinical data on efficacy of everolimus in HR+ HER2-MBC after cancer progresses on CDK4/6 inhibitors.
Objective
The objective of this study is to find the efficacy of everolimus in HR+ HER2-MBC after they progress on a CDK4/6 inhibitor palbociclib.
Methods
This is a retrospective, 2-institute review of HR+ HER2-MBC from Jan 2015 to March 2018 treated with everolimus after progression on palbociclib. Primary end point was median progression-free survival (PFS), secondary end points objective response rate (ORR), clinical benefit ratio (CBR), and overall survival (OS).
Results
Out of 41 women with median age 61 years (33, 87) enrolled, 66% had received adjuvant systemic therapy, 61% had visceral disease, and 95% had prior nonsteroidal aromatase inhibitors. About 83% women had 3 or more chemotherapy or hormonal therapies prior to everolimus. Kaplan-Meier estimates showed a median PFS of 4.2 months (95% confidence interval [CI]: 3.2-6.2). The median OS was 18.7 months (95% CI 9.5 to not reached). Objective response rate and CBR were both 17.1%.
Conclusion
Everolimus was associated with modest PFS and ORR in HR+ HER2-MBCs postprogression on palbociclib.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
- Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
- Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
ORCID-Profile: Ajay Dhakal, Matthew G Hanna, Austin Miller, Mateusz Opyrchal
Förderung
- NCI NIH HHS
- national cancer institute
- Clinical Data Network Shared Resources
Zitieren
APA
Dhakal, A., Antony Thomas, R., Levine, E. G., Brufsky, A., Takabe, K., Hanna, M. G., Attwood, K., Miller, A., Khoury, T., Early, A. P., Soniwala, S., O'Connor, T., & Opyrchal, M. (2020). Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib. Breast Cancer: Basic and Clinical Research, 14. https://doi.org/10.1177/1178223420944864
Vancouver
Dhakal A, Antony Thomas R, Levine EG, Brufsky A, Takabe K, Hanna MG, et al. Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib. Breast Cancer: Basic and Clinical Research. 2020;14. doi:10.1177/1178223420944864
BibTeX
@article{Dhakal2020,
author = {Dhakal, Ajay and Antony Thomas, Roby and Levine, Ellis G and Brufsky, Adam and Takabe, Kazuaki and Hanna, Matthew G and Attwood, Kristopher and Miller, Austin and Khoury, Thaer and Early, Amy P and Soniwala, Saif and O'Connor, Tracy and Opyrchal, Mateusz},
title = {Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib},
journal = {Breast Cancer: Basic and Clinical Research},
year = {2020},
volume = {14},
doi = {10.1177/1178223420944864}
}
EUVIMED